BDSX

Biodesix, Inc. (BDSX) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. Biodesix, Inc. is a diagnostic solutions company focused on lung disease, offering blood-based diagnostic tests (Nodify Lung and IQLung strategies) and development services to biopharmaceutical companies. The company operates as a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Revenue Breakdown (Q2 2026): Diagnostic Tests generated $25.3 million (94% of revenue), while Development Services generated $1.5 million.

Gross Margin: 82% for Q2 2026, an improvement of 200 basis points year-over-year.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 34% in Q2 2026 and 38% YTD compared to 2025. Diagnostic Tests revenue grew 42% in Q2, driven by a 38% increase in test volumes (20,900 tests) and higher average revenue per test due to expanded payer coverage.
• Profitability Improvement: Net loss narrowed by 37% in Q2 2026 compared to the prior year. Operating loss improved by 45% due to revenue growth outpacing operating expense increases.
• Expense Management: Operating expenses (excluding direct costs) increased 7% in Q2. Share-based compensation decreased 21% year-over-year to $0.8 million. Direct costs increased 20% primarily due to higher testing volume, partially offset by a one-time $0.4 million recovery of sales and use taxes in Q1 2026.
• Liquidity: Cash and cash equivalents increased to $30.0 million from $19.0 million at the start of the year, bolstered by $23.9 million in gross proceeds from the At-The-Market (ATM) equity program.

Guidance, Outlook, and Risks

Management Commentary: Management highlights strong gross margins driven by volume and workflow optimization. The company expects continued operating leverage as the sales team gains productivity. The Development Services pipeline is described as strong, supporting growth expectations for the remainder of 2026.

Capital Structure & Debt: The company holds a $50.0 million Perceptive Term Loan Facility. In February 2026, the maturity date was extended to November 2028. The loan requires a minimum cash balance of $2.5 million and specific revenue thresholds. Interest rates are variable (SOFR + 9.0% margin).

Risks and Contingencies:

• Reimbursement Risk: Revenue is heavily dependent on third-party payer coverage. Changes in policies, claims reviews, or enforcement priorities (e.g., potential "CRUSH" rule) could impact reimbursement rates and timing.
• Liquidity Needs: The company has a history of net operating losses and relies on equity financing (ATM program) and debt to fund operations. It has $18.8 million remaining capacity under its 2024 ATM program.
• Supply Chain: Reliance on single-source suppliers for certain test components creates vulnerability to supply disruptions.
• Regulatory: Risks associated with FDA requirements, product recalls, and the need for regulatory clearance for new tests.

Investor Verification Checklist

• Reimbursement Trends: Verify the sustainability of the "higher average revenue per test" and the status of contracts with major payers (United Healthcare, Humana, Medicare).
• Debt Covenants: Confirm continued compliance with the Perceptive Term Loan covenants, specifically the $2.5 million minimum cash balance and revenue thresholds through 2028.
• ATM Program Utilization: Monitor the remaining $18.8 million capacity and the weighted average price of shares sold to assess dilution impact.
• One-Time Items: Note the $0.4 million tax recovery in Q1 2026 which artificially lowered direct costs; exclude this when projecting future cost trends.
• Clinical Study Milestones: Track the completion of the INSIGHT and ALTITUDE studies and the progress of the CLARIFY study, as these are critical for future payer coverage expansion.